A critique of semaglutide (Wegovy®) for obesity management NICE technology appraisal TA875

Authors

  • Hassan Kahal North Bristol NHS Trust
  • Chris Walton Hull University Teaching Hospitals NHS Trust

DOI:

https://doi.org/10.15277/bjd.2024.439

Keywords:

obesity, Wegovy®, semaglutide, NICE TA875

Abstract

Wegovy®, semaglutide 2.4 mg, is a glucagon-like peptide-1 analogue that has been approved by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with obesity in the National Health Service (NHS). In this review, we provide a reflection on NICE TA875 and its implementation in the NHS.

Author Biography

Hassan Kahal, North Bristol NHS Trust

Consultant in Diabetes and Endocrinology in Bristol 

References

https://www.nice.org.uk/guidance/ta875; accessed on 5/10/2023

Wilding JPH, Batterham RL, Calanna S, et al.; the STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183

Davies M, Færch L, Jeppesen OK, et al.; the STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397(10278):971-84. https://doi.org/10.1016/S0140-6736(21)00213-0

Wadden TA, Bailey TS, Billings LK, et al.; the STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021;325(14):1403-13. https://doi.org/10.1001/jama.2021.1831

Rubino D, Abrahamsson N, Davies M, et al.; the STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325(14):1–12. https://doi.org/10.1001/jama.2021.3224

Garvey WT, Batterham RL, Bhatta M, et al.; the STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28(10):2083-91. https://doi.org/10.1038/s41591-022-02026-4

Kadowaki T, Isendahl J, Khalid U, et al.; STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol 2022;10(3):193-206. https://doi.org/10.1016/S2213-8587(22)00008-0.

Rubino DM, Greenway FL, Khalid U, et al.; the STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. The STEP 8 Randomized Clinical Trial. JAMA 2022;327(2):138-150. https://doi.org/10.1001/jama.2021.23619.

https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2019/health-survey-for-england-2019-data-tables; accessed 05/10/2023.

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; for the SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-32. https://doi.org/10.1056/NEJMoa2307563.

Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.; the STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389(12):1069-84. https://doi.org/10.1056/NEJMoa2306963.

Wilding JPH, Batterham RL, Davies M, et al.; the STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553–64. https://doi.org/10.1111/dom.14725.

https://www.nice.org.uk/guidance/TA924; accessed on 07/06/2024

Downloads

Published

2024-06-29

Issue

Section

Reviews

Most read articles by the same author(s)